Search Results 1081-1090 of 18628 for Relapse

  1. Ricardo D. Parrondo, M.D. - Doctors and Medical Staff - Mayo Clinic

    Expertise in management of relapsed/refractory plasma cell dyscrasias; Development of early and late-phase clinical trials for plasma cell dyscrasias ...

  2. Oncology (Medical) - Clinical trials

    ... Relapsed or Refractory NHL. The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or ...

  3. Medical Research & Education - Mayo Clinic News Network

    Root Cause of Multiple Myeloma Relapse Revealed. Dana Sparks. September 18, 2013. Cancer. Mayo Clinic Receives $8.8 Million Federal Grant for Metabolomics ...

  4. Efficacy And Safety Of Nemtabrutinib (MK-1026) In Participants With Hematologic Malignancies (MK-1026-003) - Mayo Clinic

    ... relapsed or refractory following at least 1 line of prior therapy * Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior ...

  5. Graft-Versus-Host Disease Clinical Trials - Mayo Clinic Research

    This study aims to determine if any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free survival at one year after ...

  6. A Study to Evaluate Tadalafil and Lenalidomide with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma - Mayo Clinic

    Relapsed myeloma patients that have not previously had a transplant. Meeting criteria for high-risk disease. Measurable serum and/or urine M-protein from ...

  7. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

    ... relapsed with no available curative options. Part 2 (Cohort Expansion): At ... Part 1 (Dose Escalation): Hematological malignancy has been previously treated, has ...

  8. Teen depression - Symptoms and causes - Mayo Clinic

    Maintain ongoing treatment, if recommended, even after symptoms let up, to help prevent a relapse of depression symptoms. By Mayo Clinic Staff · Teen ...

  9. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    AI failures: Disease that relapsed during treatment or within 12 months of completion of adjuvant therapy with an AI, OR disease that progressed during ...

  10. Dr. Dean Wingerchuk Archives - Mayo Clinic News Network

    ... relapse, disability can worsen. It affects up to 10 in 100,000 people. Currently, the immunosuppressive therapies used to prevent neuromyelitis optica relapses ...